CVS Group Regulatory News (CVSG)

26 May 2026

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Changes to Non-Executive Director Responsibilities

CVS, the UK listed veterinary group and a leading provider of veterinary services, is pleased to announce a change in responsibilities for one of the recently appointed Non-Executive Directors.

Laura Hagan, Independent Non-Executive Director, will be appointed as Senior Independent Director and Employee Engagement Director with effect from 1 July 2026.

Laura succeeds Deborah Kemp, who will step down from the roles of Senior Independent Director, Employee Engagement Director and Remuneration Committee Chair with effect from 30 June 2026. As previously announced, Deborah, who joined the Board in January 2018, will retire and step down from the Board and all board committees on that date.

Helen Keays, Independent Non-Executive Director and Chair designate of the Remuneration Committee, will become Chair of the Remuneration Committee with effect from 1 July 2026.

This announcement is made pursuant to UKLR 6.4.6.

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.